GlassScriptPhysician profile
Matthew G Mcmenemy
NPI 1700842267
$150,061.37
in general payments reported to CMS, 2019-2025
38 companies · $31K in 2025
The $31K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $5,211 · 2021: $23K · 2022: $21K · 2023: $11K · 2024: $25K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $53K · Food and Beverage: $9,735 · Travel and Lodging: $2,472 · Consulting Fee: $1,725 · Long Term Medical Supply Or Device Loan: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $52,575.00 |
| Food and Beverage | $9,735.11 |
| Travel and Lodging | $2,471.59 |
| Consulting Fee | $1,725.00 |
| Long Term Medical Supply Or Device Loan | $769.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $77,195.77 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32,110.12 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $17,825.01 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $4,772.18 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $2,449.66 | 2021-2024 | Eylea Hd, Eylea |
| Alcon Vision LLC | $2,396.20 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $2,007.10 | 2019-2025 | Tecnis Iol, Catalys System |
| Abbvie INC. | $1,482.68 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,194.90 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $1,178.33 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $1,094.49 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $830.63 | 2021-2025 | Lumera 300, Cirrus Hd-Oct |
| Allergan, INC. | $790.75 | 2019-2022 | |
| Sight Sciences, INC. | $660.27 | 2019-2025 | Omni Surgical System, Tearcare System |
| Harrow Eye, LLC | $549.85 | 2024-2025 | Vevye |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $523.05 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $487.34 | 2021-2023 | Tepezza |
| Oyster Point Pharma, INC. | $385.34 | 2022-2025 | Tyrvaya, Ryzumvi |
| Amgen INC. | $375.76 | 2024-2025 | Tepezza |
| Dompe US, INC. | $268.38 | 2022-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $214.98 | 2020-2023 | Eylea Hd |
| Shire North American Group INC | $208.29 | 2019 | |
| Biotissue Holdings INC. | $201.69 | 2019-2024 | |
| Thea Pharma INC. | $162.00 | 2023-2025 | Iyuzeh |
| Incyte Corporation | $152.73 | 2021-2022 | |
| Ocular Therapeutix, INC. | $125.73 | 2024 | Dextenza |
| Beaver-Visitec International, INC. | $82.62 | 2021 | |
| Mallinckrodt Hospital Products INC. | $68.86 | 2024 | Acthar |
| Astellas Pharma US INC | $63.54 | 2023-2024 | Izervay |
| Glaukos Corporation | $53.30 | 2023-2025 | Idosetr |
| Optos, INC. | $32.33 | 2021 | |
| Mallinckrodt Enterprises LLC | $24.27 | 2019 | |
| Recordati_rare_diseases_inc. | $22.10 | 2024 | Panhematin |
| New World Medical,INC. | $19.12 | 2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Coopervision INC. | $18.55 | 2019 | |
| Rxsight INC | $18.51 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $14.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcmenemy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.